Home/Pipeline/Second therapeutic candidate

Second therapeutic candidate

TDP43 proteinopathy

Phase 1Active

Key Facts

Indication
TDP43 proteinopathy
Phase
Phase 1
Status
Active
Company

About SOCIUM

Socium uses AI-driven phosphorylation analysis to discover and develop novel therapeutics for neurodegenerative diseases with high unmet need.

View full company profile